Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01837498 · ClinicalTrials.gov registry record
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients
A clinical trial, sponsored by Endeavor Health.
- Completed
- Registry status
- 200
- Enrollment target
NCT01837498 is a clinical trial that has completed, run by Endeavor Health. The registered enrollment target is 200 participants.
The verdict
NCT01837498 has completed, sponsored by Endeavor Health.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
The majority of patients undergoing surgery receive neuromuscular blocking agents (NMBAs) in the operating room. Reversal of neuromuscular blockade at the conclusion of a general anesthetic is accomplished with cholinesterase inhibitors (primarily neostigmine). Although these drugs are often effective in enhancing recovery of muscle strength, the onset of effect is often slow (usually 15-30 minutes). More effective neuromuscular reversal agents are needed in clinical practice to enhance surgical and anesthetic management of perioperative patients. A new reversal agent (sugammadex) will likely be approved for clinical use in the United States next year. Unlike neostigmine, sugammadex is effective in providing rapid antagonism of all levels of neuromuscular blockade (typically within 2-4 minutes). The aim of this prospective observational study is to study neuromuscular and clinical recovery in 100 consecutive thoracic surgical patients receiving neostigmine, followed by a 100 consecutive thoracic surgical patients administered sugammadex (after the drug is approved by the FDA). In addition, after data on 100 patients reversed with neostigmine is collected, the data will be analyzed to compare patients with residual block (train-of four \< 0.9) and without residual block (TOF \</= 0.9)
Interventions
- DRUG Sugammadex
- DRUG Neostigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2014-02 |
| Est. Completion | 2017-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01837498
The ClinicalTrials.gov registry entry for NCT01837498 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sugammadex is the first listed.
NCT01837498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01837498 about?
NCT01837498 is a clinical study titled "Reversal of Neuromuscular Blockade in Thoracic Surgical Patients". The majority of patients undergoing surgery receive neuromuscular blocking agents (NMBAs) in the operating room. Reversal of neuromuscular blockade at the conclusion of a general anesthetic is accomplished with cholinesterase inhibitors (primarily neostigmine). Although these drugs are often effecti...
What is the current status of trial NCT01837498?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2014-02. Estimated completion is 2017-03.
What interventions are being tested in trial NCT01837498?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine (DRUG).
Who is sponsoring clinical trial NCT01837498?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.